TNG-908 is a small molecule commercialized by Tango Therapeutics, with a leading Phase II program in Squamous Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of TNG-908’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for TNG-908 is expected to reach an annual total of $77 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

TNG-908 Overview

TNG-908 is under development for the treatment of MTAP-deleted cancers like cholangiocarcinoma, mesothelioma, squamous and non squamous non-small cell lung cancer, bladder cancer, diffuse large b-cell lymphoma, malignant peripheral nerve sheath tumor (MPNST)glioblastoma multiforme, colon cancer. It is administered through oral route. It acts by targeting the protein arginine methyltransferase 5 (PRMT5) enzyme.

Tango Therapeutics Overview

Tango Therapeutics, formerly Tango Therapeutics, is a biotechnology company that discovers and develops novel drug targets for the treatment of cancer. The company is investigating TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) against methylthioadenosine phosphorylase (MTAP) deleted cancers. It is also developing drugs for BRCA1-mutant breast, ovarian and prostate cancer, lung cancer, and solid tumors. Tango Therapeutics utilizes CRISPR (clustered regularly interspaced short palindromic repeats) based functional genomics target discovery platform to detect novel synthetic lethal targets for loss or deactivation of multiple tumor suppressor genes. It works in collaboration with Gilead Sciences to discover, develop, and commercialize cancer therapies. Tango Therapeutics is headquartered in Boston, Massachusetts, the US.

The company reported revenues of (US Dollars) US$37 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$58.2 million in FY2021, compared to an operating loss of US$0.2 million in FY2020. The net loss of the company was US$58.2 million in FY2021, compared to a net loss of US$0.1 million in FY2020. The company reported revenues of US$6.9 million for the third quarter ended September 2022, an increase of 19.9% over the previous quarter.

For a complete picture of TNG-908’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.